Citations

Clear

29 citation(s) found for "Larson, Timothy".

Outcomes In the Pre-Rituximab and Post-Rituximab Eras In Post-Transplantation Lymphoproliferative Disorders (PTLD) In Adult Solid Organ Transplant Recipients
Ristow, Kay M., Macon, William R. , Larson, Timothy S., Kudva, Yogis, Walker, Randall C., Wiesner, Russell H., Edwards, Brooks S., Ansell, Stephen M. , Habermann, Thomas M. , Maurer, Matthew J.

Mayo Clinic

Blood | October 12, 2019 | Volume: 116 | Issue: 21 | Pages: 2859-2859

10.1182/blood.v116.21.2859.2859 Get It

Abstract Abstract 2859 Background: PTLD is the most common malignancy, other than melanomatous skin cancer complicating solid organ transplantation and has been one of the most commonly observed fatal consequences. The histologies are diverse and include B-cell, T-cell and Hodgkin lymphomas. Rituximab has affected the outcome in CD20+ patients with PTLD. This single institution study sought to identity the outcomes in patients of all histologies and presentations managed in the post-rituximab era. Methods: Patients with solid organ transplantation who were diagnosed with PTLD at Mayo Clinic (Rochester, MN) between December 1970 and October 2009 were identified through the Mayo Clinic Lymphoma Data Base. The rituximab era was defined as patients diagnosed after December 26, 2000, the date of diagnosis for the first patient treated with rituximab in our series. Cox proportional hazards models were used to assess the association of clinical factors and overall survival (OS). Results: 143 patients diagnosed with PTLD between December 1970 and October 2009 were identified. The median age at the time of diagnosis of PTLD was 50 years (range 15–84) with 41 patients (29%) over the age of 60. 93 were male (65%). At a median follow-up of 84 months (range 1–295), 95 patients (65%) have died. The types of organ transplant included renal (39%), liver (31%), cardiac (11%), lung (6%), renal/pancreas (6%), pancreas (4%), and multiorgan (4%). 83% of patients presented with extranodal disease. 28% had involvement of the engrafted organ. 76% of the patients developed PTLD that was EBV+ by in situ hybridization. 62% were stage 3–4. The IPI was intermediate-high in 39% of patients. Initial approaches to management included reduction in immunosuppression (45%), chemotherapy (12%), reduction in immunosuppression with rituximab (12%), rituximab (8%), and radiation therapy (6%). The overall response to therapeutic approaches was 46% in the pre-rituximab era and 56% in the post-rituximab era (chi-squared p=0.25). Patients treated with rituximab had an improved overall survival (HR = 1.66, 95% CI: 0.99–2.79). Patients treated in the rituximab era had improved 1 year survival (76%) compared to patients in the pre-rituximab era (59%) (chi-squared p=0.03). However, the survival advantage in the rituximab era was not maintained in longer follow-up. The median overall survival in the pre-rituximab era was 31 months compared to 56 months in the post-rituximab era (logrank p=0.63). Conclusion: The overall response rates and overall survival are improved with rituximab treatment in CD20+ PTLD, however, the natural history of all PTLD has not improved significantly in the post-rituximab era. New approaches are needed for the prevention and management of all the histologies of PTLD. Disclosures: No relevant conflicts of interest to declare.
Role of nitric oxide in intrarenal hemodynamics in experimental diabetes mellitus in rats
Pflueger, Axel , Larson, Timothy S., Hagl, Siegfried, Knox, Franklyn G.

Mayo Clinic

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | December 25, 2017 | Volume: 277 | Issue: 3 | Pages: R725-R733

10.1152/ajpregu.1999.277.3.r725 | PMID 10484489 Get It

The role of nitric oxide (NO) in the regulation of the intrarenal microcirculation in streptozotocin (STZ)-induced diabetes mellitus in rats is not clear. We examined renal cortical and papillary hemodynamics in STZ rats and determined the effects of systemic inhibition and stimulation of NO synthesis. Renal blood flow in cortical (QCC), and inner medullary ascending (QAV) and descending (QDV) vasa recta capillaries was measured by fluorescence videomicroscopy in STZ Munich-Wistar rats and nondiabetic control rats. Ten days after STZ injection (80 mg/kg ip), basal QCCand QDVwere significantly greater in STZ rats ( n = 16) compared with control rats ( n = 15). Infusion of NG-monomethyl-l-arginine (l-NMMA, 15 mg/kg bolus, 500 μg ⋅ min−1⋅ kg−1iv) decreased QCC(−41%), QAV(−38%), and QDV(−37%) in control rats ( n = 6) and to a significantly greater magnitude than in STZ rats ( n = 7), QCC(−14%), QAV(−20%), and QDV(−25%). Coinfusion ofl-arginine (l-Arg, 1 mg ⋅ kg−1⋅ min−1iv) with l-NMMA increased QCCto a significantly greater extent ( P < 0.01) in control rats compared with STZ rats. In subsequent studies, infusion ofl-Arg alone increased QCC(+50%), QAV(+16%), and QDV(+11%) in control rats ( n = 5) but had no effect in STZ rats ( n = 5). These results show that the response of renal cortical and papillary capillary blood flow to both inhibition and stimulation of NO synthesis is attenuated in the early onset of STZ-diabetes mellitus rats compared with control rats.
Natriuretic response to renal interstitial hydrostatic pressure during angiotensin II blockade
Haas, J. A., Lockhart, John C. , Larson, Timothy S., Henrikson, T., Knox, Franklyn G.

Mayo Clinic

American Journal of Physiology-Renal Physiology | December 23, 2017 | Volume: 266 | Issue: 1 | Pages: F117-F119

10.1152/ajprenal.1994.266.1.f117 | PMID 8304476 Get It

Increases in renal interstitial hydrostatic pressure (RIHP) increase urinary sodium excretion (UNaV). Experimentally increasing RIHP by direct renal interstitial volume expansion (DRIVE) has been shown to decrease proximal tubule sodium reabsorption. The purpose of the present study was to investigate whether the renin-angiotensin system modulates the natriuretic response to DRIVE. Unilateral nephrectomy and implantation of two polyethylene matrices were performed 3 wk before the acute experiment. Fractional sodium excretion (FENa), RIHP, and glomerular filtration rate (GFR) were measured before and after DRIVE in control rats (n = 9) and in rats receiving the angiotensin II (ANG II) receptor antagonist, losartan potassium (10 mg/kg i.v.; n = 10). DRIVE was achieved by infusing 100 microliters of 2.5% albumin solution directly into the renal interstitium. GFR remained unchanged by DRIVE in both groups. In control animals, DRIVE significantly increased both RIHP (delta 3.8 +/- 0.5 mmHg) and FENa (delta 0.92 +/- 0.19%). In the losartan-treated group, RIHP (delta 2.8 +/- 0.4 mmHg) and FENa (delta 1.93 +/- 0.41%) also significantly increased. The natriuretic response to DRIVE was significantly enhanced during ANG II receptor blockade compared with control animals (delta UNaV/delta RIHP = 2.01 +/- 0.67 vs. 0.44 +/- 0.17 mu eq.min-1 x mmHg-1, respectively; P < 0.05). These results suggest that the blockade of angiotensin enhances the natriuretic response to increased RIHP during DRIVE.
Using Serum Creatinine To Estimate Glomerular Filtration Rate: Accuracy in Good Health and in Chronic Kidney Disease
Larson, Timothy S., Bergstralh, Erik J., Jacobsen, Steven J. , Cosio, Fernando G., Rule, Andrew D. , Slezak, Jeff M.

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 141 | Issue: 12 | Pages: 929-937

10.7326/0003-4819-141-12-200412210-00009 | PMID 15611490 Get It

Perfusion pressure and volume status determine the microvascular response of the rat kidney to NG-monomethyl-L-arginine.
Lockhart, John C. , Larson, Timothy S., Knox, Franklyn G.

Mayo Clinic

Circulation Research | June 12, 2012 | Volume: 75 | Issue: 5 | Pages: 829-835

10.1161/01.res.75.5.829 | PMID 7923628 Get It

This study investigated the role of volume status and perfusion pressure on the hemodynamic response of cortical and medullary renal capillaries to systemic inhibition of nitric oxide. NG-Monomethyl-L-arginine (L-NMMA) was infused intravenously (15-mg/kg bolus and 500-micrograms.min-1.kg-1 infusion), and blood flow in cortical capillaries (QCC) and in descending (QDVR) and ascending vasa recta (QAVR) was measured by fluorescence videomicroscopy in euvolemic and volume-expanded anesthetized Munich-Wistar rats. L-NMMA in euvolemic rats decreased vasa recta blood flow (delta QDVR, 3.97 +/- 0.80 nL/min [P < .01]; delta QAVR, 1.90 +/- 0.39 nL/min [P < .01]; n = 6) and QCC (delta QCC, 0.57 +/- 0.15 nL/min [P < .01]; n = 7) despite increases in renal perfusion pressure (RPP). Fractional excretion of sodium (FENa) remained unchanged. In volume-expanded rats, L-NMMA decreased vasa recta blood flow when RPP increased (delta QDVR, 1.42 +/- 0.79 nL/min [P = .05]; delta QAVR, 1.95 +/- 0.34 nL/min [P < .001]; n = 9) or was held constant by partial aortic occlusion (delta QDVR, 1.19 +/- 0.45 nL/min [P < .05]; delta QAVR, 1.44 +/- 0.40 nL/min [P < .01]; n = 8). QCC was unchanged by L-NMMA when RPP increased (delta QCC, 0.27 +/- 0.20 nL/min; n = 8) but decreased significantly by 0.61 +/- 0.11 nL/min (P < .01, n = 8) when increases in RPP were prevented. FENa increased when RPP increased (delta FENa, 2.47 +/- 0.51%; P < .001) and was held constant (delta FENa, 2.64 +/- 0.46%; P < .001).(ABSTRACT TRUNCATED AT 250 WORDS)
Relation between vasa recta blood flow and renal interstitial hydrostatic pressure during pressure natriuresis.
Farrugia, E, Lockhart, John C. , Larson, Timothy S.

Mayo Clinic

Circulation Research | June 12, 2012 | Volume: 71 | Issue: 5 | Pages: 1153-1158

10.1161/01.res.71.5.1153 | PMID 1394877 Get It

Pressure natriuresis may be mediated through increases in inner medullary vasa recta blood flow (QVR). By means of acute renal decapsulation to prevent increases in renal interstitial hydrostatic pressure (RIHP), the effect of increases in QVR in the presence and absence of changes in RIHP in the natriuretic and diuretic responses to increases in renal perfusion pressure (RPP) was evaluated. Blood flow in descending (QDVR) and ascending (QAVR) vasa recta was determined in the exposed papilla by fluorescence videomicroscopy in anesthetized euvolemic Munich Wistar rats. In rats with intact renal capsules (n = 12), increases in RPP from 101 +/- 0.5 to 132 +/- 2.9 mm Hg caused significant increases in QDVR (from 4.7 +/- 0.9 to 5.5 +/- 0.9 nl/min, p < 0.001) and QAVR (from 2.8 +/- 0.2 to 3.5 +/- 0.2 nl/min, p < 0.001) in association with increases in RIHP (from 4.6 +/- 1.3 to 7.6 +/- 1.3 mm Hg, p < 0.001), urine flow (from 16.2 +/- 2.6 to 20.2 +/- 3.2 microliters.min-1 x g kidney wt-1, p < 0.01), and urinary sodium excretion (from 2.10 +/- 0.38 to 3.36 +/- 0.62 mu eq.min-1 x g kidney wt-1, p < 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
Importance of Cystatin C Assay Standardization
Voskoboev, Nikolay, Larson, Timothy S., Rule, Andrew D. , Lieske, John C.

Mayo Clinic

Clinical Chemistry | June 11, 2011 | Volume: 57 | Issue: 8 | Pages: 1209-1211

10.1373/clinchem.2011.164798 | PMID 21666068 Get It

Iothalamate Quantification by Tandem Mass Spectrometry to Measure Glomerular Filtration Rate
Seegmiller, Jesse C. , Burns, Bradley E., Fauq, Abdul H. , Mukhtar, Naveen, Larson, Timothy S., Lieske, John C.

Mayo Clinic

Clinical Chemistry | February 19, 2010 | Volume: 56 | Issue: 4 | Pages: 568-574

10.1373/clinchem.2009.133751 | PMID 20167698 Get It

Abstract Background: Glomerular filtration rate (GFR) can be determined by measuring renal clearance of the radiocontrast agent iothalamate. Current analytic methods for quantifying iothalamate concentrations in plasma and urine using liquid chromatography or capillary electrophoresis have limitations such as long analysis times and susceptibility to interferences. We developed a liquid chromatography–tandem mass spectrometry (LC-MS/MS) method to overcome these limitations. Methods: Urine and plasma samples were deproteinized using acetonitrile and centrifugation. The supernatant was diluted in water and analyzed by LC-MS/MS using a water:methanol gradient. We monitored 4 multiple reaction monitoring transitions: m/z 614.8–487.0, 614.8–456.0, 614.8–361.1, and 614.8–177.1. We compared the results to those obtained via our standard capillary electrophoresis (CE-UV) on samples from 53 patients undergoing clinical GFR testing. Results: Mean recovery was 90%–110% in both urine and plasma matrices. Imprecision was ≤15% for the m/z 614.8–487.0 and 614.8–456.0 transitions over a 10-day period at 1 mg/L. Method comparison for 159 patient samples (53 clearances) provided the following Passing–Bablok regressions: plasma iothalamate LC-MS/MS (y) vs CE-UV (x), y = 0.99x + 0.36; urine iothalamate LC-MS/MS vs CE-UV, y = 1.01x + 0.31; corrected GFR LC-MS/MS vs CE-UV, y = 1.00x + 0.00. Interfering substances prevented accurate iothalamate quantification by CE-UV in 2 patients, whereas these samples could be analyzed by LC-MS/MS. Conclusions: Iothalamate can be quantified by LC-MS/MS for GFR measurement. This method circumvents potential problems with interfering substances that occasionally confound accurate GFR determinations.
Comparison of Urinary Albumin Quantification by Immunoturbidimetry, Competitive Immunoassay, and Protein-Cleavage Liquid Chromatography–Tandem Mass Spectrometry
Seegmiller, Jesse C. , Sviridov, Denis, Larson, Timothy S., Borland, Timothy M., Hortin, Glen L. , Lieske, John C.

Mayo Clinic

Clinical Chemistry | September 10, 2009 | Volume: 55 | Issue: 11 | Pages: 1991-1994

10.1373/clinchem.2009.129833 | PMID 19745060 Get It

Abstract Background: Increased urinary albumin excretion is a well-documented diagnostic and prognostic biomarker for renal disease. Urinary albumin is typically measured in clinical settings by immunoassay methods. However, neither a reference method nor a urine albumin calibration reference material is currently available. Methods: We quantified urinary albumin in patient samples by using 3 commercially available reagent systems: DiaSorin SPQ™ and Beckman Coulter LX® 20 (immunoturbidimetric), and Siemens Immulite® (competitive immunoassay). Results were compared to values obtained by protein-cleavage liquid chromatography–tandem mass spectrometry (LC-MS/MS). Results: In general, results from the 3 immunoassays agreed with results from LC-MS/MS. However, the SPQ results showed a negative bias across all ranges of albuminuria [(0–200 mg/L, y = 0.91x – 3.74 (CI 0.86–0.96); &gt; 200 mg/L, y = 0.88x – 40.30 (CI 0.76–1.00)], whereas the LX 20 showed minimal bias in the 0–200 mg/L range [y = 0.97x − 88 (CI 0.92–1.02)] and the Immulite assay showed positive bias in the 0–200 mg/L range [y = 1.15x – 4.38 (CI 1.09–1.20)]. Conclusions: These results showed a reasonable quantification of urinary albumin by representative polyclonal and monoclonal immunoassays compared to an LC-MS/MS assay. In addition, the results do not suggest the presence of nonimmunoreactive albumin in urine. However, differences in analytic performance between assays support the need for a reference calibration material and reference method to standardize clinical laboratory measurements of urinary albumin.
Quantification of Urinary Albumin by Using Protein Cleavage and LC-MS/MS
Seegmiller, Jesse C. , Barnidge, David R. , Burns, Bradley E., Larson, Timothy S., Kumar, Rajiv , Lieske, John C. , Kumar, Rajiv

Mayo Clinic

Clinical Chemistry | March 27, 2009 | Volume: 55 | Issue: 6 | Pages: 1100-1107

10.1373/clinchem.2008.115543 | PMID 19325011 Get It

Abstract Background: Urinary albumin excretion is a sensitive diagnostic and prognostic marker for renal disease. Therefore, measurement of urinary albumin must be accurate and precise. We have developed a method to quantify intact urinary albumin with a low limit of quantification (LOQ). Methods: We constructed an external calibration curve using purified human serum albumin (HSA) added to a charcoal-stripped urine matrix. We then added an internal standard, 15N-labeled recombinant HSA (15NrHSA), to the calibrators, controls, and patient urine samples. The samples were reduced, alkylated, and digested with trypsin. The concentration of albumin in each sample was determined by liquid chromatography–tandem mass spectrometry (LC-MS/MS) and linear regression analysis, in which the relative abundance area ratio of the tryptic peptides 42LVNEVTEFAK51 and 526QTALVELVK534 from albumin and 15NrHSA were referenced to the calibration curve. Results: The lower limit of quantification was 3.13 mg/L, and the linear dynamic range was 3.13–200 mg/L. Replicate digests from low, medium, and high controls (n = 5) gave intraassay imprecision CVs of 2.8%–11.0% for the peptide 42LVNEVTEFAK51, and 1.9%–12.3% for the 526QTALVELVK534 peptide. Interassay imprecision of the controls for a period of 10 consecutive days (n = 10) yielded CVs of 1.5%–14.8% for the 42LVNEVTEFAK51 peptide, and 6.4%–14.1% for the 526QTALVELVK534 peptide. For the 42LVNEVTEFAK51 peptide, a method comparison between LC-MS/MS and an immunoturbidometric method for 138 patient samples gave an R2 value of 0.97 and a regression line of y = 0.99x + 23.16. Conclusions: Urinary albumin can be quantified by a protein cleavage LC-MS/MS method using a 15NrHSA internal standard. This method provides improved analytical performance in the clinically relevant range compared to a commercially available immunoturbidometric assay.